3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
2
Completed
2
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
47
Breast Neoplasms
39
Ovarian Neoplasms
35
Triple Negative Breast Neoplasms
24
Endometrial Neoplasms
20
Stomach Neoplasms
19
Squamous Cell Carcinoma of Head and Neck
17
Fallopian Tube Neoplasms
17
Lung Neoplasms
16
Esophageal Squamous Cell Carcinoma
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Neoplasm Metastasis
13
Esophageal Neoplasms
13
Neoplasms
12
Uterine Cervical Neoplasms
11
Carcinoma, Ovarian Epithelial
10
Head and Neck Neoplasms
7
Recurrence
6
Carcinoma
6
Colorectal Neoplasms
5
Adenocarcinoma
5
Uterine Neoplasms
4
Small Cell Lung Carcinoma
4
Oropharyngeal Neoplasms
4
Melanoma
4
Carcinoma, Transitional Cell
4
Advanced Solid Tumors
4
Adenocarcinoma Of Esophagus
4
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Interventions
pembrolizumab
3
Doxorubicin
3
Standard of Care
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Watchful Waiting
1
Trastuzumab
1
STA 9090
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hemangiosarcoma
×
Paclitaxel
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled